Denufosol tetrasodium
| Code | Size | Price |
|---|
| TAR-T27146-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Denufosol is a P2Y2 agonist potentially for the treatment of cystic fibrosis.
CAS:
318250-11-2
Formula:
C18H23N5Na4O21P4
Molecular Weight:
861.25
Purity:
0.98
SMILES:
[Na+].[Na+].[Na+].[Na+].Nc1ccn(C2CC(O)C(COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OCC3OC(C(O)C3O)n3ccc(=O)[nH]c3=O)O2)c(=O)n1
References
1. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013 Apr;162(4):676-80. doi: 10.1016/j.jpeds.2012.11.034. Epub 2013 Jan 3. PubMed PMID: 23290508.
2. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 10.1016/j.jcf.2012.05.003. Epub 2012 Jun 8. PubMed PMID: 22682898.
3. Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW; TIGER-1 Investigator Study Group. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med. 2011 Mar 1;183(5):627-34. doi: 10.1164/rccm.201008-1267OC. Epub 2010 Dec 17. PubMed PMID: 21169471.
4. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm Pharmacol Ther. 2008 Aug;21(4):600-7. doi: 10.1016/j.pupt.2007.12.003. Epub 2007 Dec 31. Review. PubMed PMID: 18276176.